Star Combo Pharma Limited engages in the manufacture and distribution of health food products and nutritional supplements in Australia and China.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.32|
|52 Week High||AU$0.23|
|52 Week Low||AU$0.40|
|1 Month Change||-7.35%|
|3 Month Change||8.62%|
|1 Year Change||-8.70%|
|3 Year Change||-53.68%|
|5 Year Change||n/a|
|Change since IPO||-60.13%|
Recent News & Updates
Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think
Shareholders didn't seem to be thrilled with Star Combo Pharma Limited's ( ASX:S66 ) recent earnings report, despite...
|S66||AU Personal Products||AU Market|
Return vs Industry: S66 underperformed the Australian Personal Products industry which returned 18.7% over the past year.
Return vs Market: S66 underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: Insufficient data to determine S66's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine S66's volatility change over the past year.
About the Company
Star Combo Pharma Limited engages in the manufacture and distribution of health food products and nutritional supplements in Australia and China. The company operates through two segments, Star Combo and Austoyou Retail. It develops, manufactures, markets, and sells natural health supplements and skin care products.
Star Combo Pharma Fundamentals Summary
|S66 fundamental statistics|
Is S66 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|S66 income statement (TTM)|
|Cost of Revenue||AU$23.54m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.058|
|Net Profit Margin||-29.20%|
How did S66 perform over the long term?See historical performance and comparison
Is Star Combo Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate S66's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate S66's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: S66 is unprofitable, so we can't compare its PE Ratio to the Global Personal Products industry average.
PE vs Market: S66 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate S66's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: S66 is good value based on its PB Ratio (1.2x) compared to the AU Personal Products industry average (2.9x).
How is Star Combo Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Star Combo Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Star Combo Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: S66 is currently unprofitable.
Growing Profit Margin: S66 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: S66 is unprofitable, and losses have increased over the past 5 years at a rate of 37.4% per year.
Accelerating Growth: Unable to compare S66's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: S66 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (23%).
Return on Equity
High ROE: S66 has a negative Return on Equity (-21.76%), as it is currently unprofitable.
How is Star Combo Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: S66's short term assets (A$26.4M) exceed its short term liabilities (A$3.5M).
Long Term Liabilities: S66's short term assets (A$26.4M) exceed its long term liabilities (A$3.6M).
Debt to Equity History and Analysis
Debt Level: S66's debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if S66's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: S66 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: S66 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 26.1% each year
What is Star Combo Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate S66's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate S66's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if S66's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if S66's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of S66's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Ms. Su Zhang, MBA, GradCertComm, BPharm serves as Chief Executive Officer at Star Combo Pharma Ltd since November 2018 and serves as its Executive Director since 2018. She served as Director at Star Combo...
CEO Compensation Analysis
Compensation vs Market: Su's total compensation ($USD135.73K) is below average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Su's compensation has increased whilst the company is unprofitable.
Experienced Board: S66's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Star Combo Pharma Limited's employee growth, exchange listings and data sources
- Name: Star Combo Pharma Limited
- Ticker: S66
- Exchange: ASX
- Founded: 2004
- Industry: Personal Products
- Sector: Household
- Market Cap: AU$42.460m
- Shares outstanding: 134.79m
- Website: https://www.starcombo.com.au
- Star Combo Pharma Limited
- 171-177 Woodpark Road
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 07:05|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.